GAK and cholangiocarcinoma: A multitude of cancers would be good clinical candidates for specific GAK inhibitors including cholangiocarcinoma, as epithelial bile duct cancers are one of the highest mutated FBXW7 tumours, have poor prognosis and a paucity of therapeutic agents (Meza-Junco et al, 2010).